195 related articles for article (PubMed ID: 38303689)
1. Decrease in multiple complement proteins associated with development of islet autoimmunity and type 1 diabetes.
Webb-Robertson BM; Nakayasu ES; Dong F; Waugh KC; Flores JE; Bramer LM; Schepmoes AA; Gao Y; Fillmore TL; Onengut-Gumuscu S; Frazer-Abel A; Rich SS; Holers VM; Metz TO; Rewers MJ
iScience; 2024 Feb; 27(2):108769. PubMed ID: 38303689
[TBL] [Abstract][Full Text] [Related]
2. Decrease in multiple complement protein levels is associated with the development of islet autoimmunity and type 1 diabetes.
Webb-Robertson BM; Nakayasu ES; Dong F; Waugh KC; Flores J; Bramer LM; Schepmoes A; Gao Y; Fillmore T; Onengut-Gumuscu S; Frazer-Abel A; Rich SS; Holers VM; Metz TO; Rewers MJ
medRxiv; 2023 Jul; ():. PubMed ID: 37502972
[TBL] [Abstract][Full Text] [Related]
3. The Multifactorial Progression from the Islet Autoimmunity to Type 1 Diabetes in Children.
Bauer W; Gyenesei A; Krętowski A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299114
[TBL] [Abstract][Full Text] [Related]
4. Plasma protein biomarkers predict the development of persistent autoantibodies and type 1 diabetes 6 months prior to the onset of autoimmunity.
Nakayasu ES; Bramer LM; Ansong C; Schepmoes AA; Fillmore TL; Gritsenko MA; Clauss TR; Gao Y; Piehowski PD; Stanfill BA; Engel DW; Orton DJ; Moore RJ; Qian WJ; Sechi S; Frohnert BI; Toppari J; Ziegler AG; Lernmark Å; Hagopian W; Akolkar B; Smith RD; Rewers MJ; Webb-Robertson BM; Metz TO;
Cell Rep Med; 2023 Jul; 4(7):101093. PubMed ID: 37390828
[TBL] [Abstract][Full Text] [Related]
5. Type 1 diabetes and autoimmunity.
Kawasaki E
Clin Pediatr Endocrinol; 2014 Oct; 23(4):99-105. PubMed ID: 25374439
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional networks in at-risk individuals identify signatures of type 1 diabetes progression.
Xhonneux LP; Knight O; Lernmark Å; Bonifacio E; Hagopian WA; Rewers MJ; She JX; Toppari J; Parikh H; Smith KGC; Ziegler AG; Akolkar B; Krischer JP; McKinney EF
Sci Transl Med; 2021 Mar; 13(587):. PubMed ID: 33790023
[TBL] [Abstract][Full Text] [Related]
7. Anti-Islet Autoantibodies in Type 1 Diabetes.
Kawasaki E
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373160
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic islet autoimmunity.
Boitard C
Presse Med; 2012 Dec; 41(12 P 2):e636-50. PubMed ID: 23182678
[TBL] [Abstract][Full Text] [Related]
9. The importance of biomarker development for monitoring type 1 diabetes progression rate and therapeutic responsiveness.
Fyvie MJ; Gillespie KM
Front Immunol; 2023; 14():1158278. PubMed ID: 37256143
[TBL] [Abstract][Full Text] [Related]
10. The Environmental Determinants of Diabetes in the Young (TEDDY) Study: 2018 Update.
Rewers M; Hyöty H; Lernmark Å; Hagopian W; She JX; Schatz D; Ziegler AG; Toppari J; Akolkar B; Krischer J;
Curr Diab Rep; 2018 Oct; 18(12):136. PubMed ID: 30353256
[TBL] [Abstract][Full Text] [Related]
11. Lessons and gaps in the prediction and prevention of type 1 diabetes.
Mameli C; Triolo TM; Chiarelli F; Rewers M; Zuccotti G; Simmons KM
Pharmacol Res; 2023 Jul; 193():106792. PubMed ID: 37201589
[TBL] [Abstract][Full Text] [Related]
12. Environmental Triggering of Type 1 Diabetes Autoimmunity.
Houeiss P; Luce S; Boitard C
Front Endocrinol (Lausanne); 2022; 13():933965. PubMed ID: 35937815
[TBL] [Abstract][Full Text] [Related]
13. Clinical and experimental treatment of type 1 diabetes.
Long SA; Buckner JH
Clin Exp Immunol; 2022 Dec; 210(2):105-113. PubMed ID: 35980300
[TBL] [Abstract][Full Text] [Related]
14. Chemokines as Drivers of the Autoimmune Destruction in Type 1 Diabetes: Opportunity for Therapeutic Intervention in Consideration of an Optimal Treatment Schedule.
Christen U; Kimmel R
Front Endocrinol (Lausanne); 2020; 11():591083. PubMed ID: 33193102
[TBL] [Abstract][Full Text] [Related]
15. Possible heterogeneity of initial pancreatic islet beta-cell autoimmunity heralding type 1 diabetes.
Lernmark Å; Akolkar B; Hagopian W; Krischer J; McIndoe R; Rewers M; Toppari J; Vehik K; Ziegler AG;
J Intern Med; 2023 Aug; 294(2):145-158. PubMed ID: 37143363
[TBL] [Abstract][Full Text] [Related]
16. Islet Autoantibodies.
Lampasona V; Liberati D
Curr Diab Rep; 2016 Jun; 16(6):53. PubMed ID: 27112957
[TBL] [Abstract][Full Text] [Related]
17. Dietary fatty acid intake in childhood and the risk of islet autoimmunity and type 1 diabetes: the DIPP birth cohort study.
Hakola L; Vuorinen AL; Takkinen HM; Niinistö S; Ahonen S; Rautanen J; Peltonen EJ; Nevalainen J; Ilonen J; Toppari J; Veijola R; Knip M; Virtanen SM
Eur J Nutr; 2023 Mar; 62(2):847-856. PubMed ID: 36284022
[TBL] [Abstract][Full Text] [Related]
18. Humoral autoimmunity in type 1 diabetes: prediction, significance, and detection of distinct disease subtypes.
Pietropaolo M; Towns R; Eisenbarth GS
Cold Spring Harb Perspect Med; 2012 Oct; 2(10):. PubMed ID: 23028135
[TBL] [Abstract][Full Text] [Related]
19. Early childhood CMV infection may decelerate the progression to clinical type 1 diabetes.
Ekman I; Vuorinen T; Knip M; Veijola R; Toppari J; Hyöty H; Kinnunen T; Ilonen J; Lempainen J
Pediatr Diabetes; 2019 Feb; 20(1):73-77. PubMed ID: 30338642
[TBL] [Abstract][Full Text] [Related]
20. Practical Clinical Applications of Islet Autoantibody Testing in Type 1 Diabetes.
Winter WE; Pittman DL; Jialal I
J Appl Lab Med; 2022 Jan; 7(1):197-205. PubMed ID: 34996067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
